3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Lymphoma, Follicular
5
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Advanced Solid Tumors
1
Interventions
Dexamethasone
64
Cyclophosphamide
35
pomalidomide
34
Lenalidomide
34
Rituximab
31
Bortezomib
30
venetoclax
28
fludarabine
27
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
17
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Injections
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
duvelisib
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts
NCT03370185
2023-02-28
BRIO
SecuraBio
Phase 2
Withdrawn